]>

IRCT201201078634N1 IRCT 2012-05-07 Vice chancellor for research, Isfahan University of Medical Sciences Comparison of standard anti-Helicobacter pylori eradication regimen with and without N Acetylcysteine in patients with dyspepsia Comparison of standard anti-Helicobacter pylori eradication regimen with and without N Acetylcysteine in patients with dyspepsia 2012-01-20 anticipated 100 Complete https://irct.ir/trial/9125 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 2-3 Dyspepsia. Intervention 1: Intervention group received standard treatment of anti H pylori which include Amoxicillin 500 mg four times daily, Bismuth citrate 120 mg four times daily, Omeprazole 20 mg twice daily, Clarithromycin 500 mg twice daily plus effervescent N Acetylcysteine 600 mg tablets 2 times a day per oral for 14 days. Intervention 2: Control group received standard treatment of anti H pylori which include Amoxicillin 500 mg four times daily, Bismuth citrate 120 mg four times daily, Omeprazole 20 mg twice daily, Clarithromycin 500 mg twice daily per oral for 14 days.

public Dr Mehdi Zobeiri

Gastrointestinal department, Azahra hospital, Soffeh Boulevard, Isfahan, Iran

Isfahan Iran (Islamic Republic of) +98 31 1624 9030 mzoberi@kums.ac.ir; mehdizobeiri@yahoo.com Kermanshah University of Medical Sciences scientific Dr Mohammad Hassan Emami

Poursina Hakim Digestive Research Center, Second Floor of behesht Building, opposite of Al Kareem mosque, Bozorgmehr St., Isfahan, Iran

Isfahan Iran (Islamic Republic of) 814651798 +98 31 1264 4020 mh_emami@med.mui.ac.ir Isfahan University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) Iran (Islamic Republic of) Inclusion criteria included: All patients with gastrointestinal symptoms and dyspepsia which refer to the Gastroenterology Clinics of Al-Zahra hospital, Noor, Poursina Hakim Research Center and Ardakan hospital for endoscopy by a gastroenterologist recruited with full consent if Helicobacter pylori tests were positive (confirmed by histology, Rapid urease test or stool antigen test). Exclusion criteria included: Patients previously received eradication of Helicobacter pylori treatment؛ Presence of underlying disease such as cirrhosis؛ Renal failure؛ Severe cardiac disease؛ malignancy outside of the GI؛ Age less than 17 and more than 80؛ Simultaneous use of NSAIDs؛ Concomitant use of steroids؛ Recent gastrointestinal bleeding؛ pregnancy or lactation. 17 years 80 years Both B98.0 Helicobacter pylori [H.pylori] as the cause of diseases classified Treatment - Drugs Treatment - Drugs Intervention group received standard treatment of anti H pylori which include Amoxicillin 500 mg four times daily, Bismuth citrate 120 mg four times daily, Omeprazole 20 mg twice daily, Clarithromycin 500 mg twice daily plus effervescent N Acetylcysteine 600 mg tablets 2 times a day per oral for 14 days. Control group received standard treatment of anti H pylori which include Amoxicillin 500 mg four times daily, Bismuth citrate 120 mg four times daily, Omeprazole 20 mg twice daily, Clarithromycin 500 mg twice daily per oral for 14 days. Helicobacter pylori eradication. Timepoint: Prior to and one month after intervention. Method of measurement: Stool antigen. Drug side effects. Timepoint: During and after drug consumption. Method of measurement: Visiting and call-chek list. Drug tolerance. Timepoint: During drug consumption. Method of measurement: Visiting and call. Vice chancellor for research, Isfahan University of Medical Sciences Approved 2010-09-16 Ethics Committee of Isfahan University of Medical Sciences Ethics Committee of Isfahan University of Medical Sciences, Vice chancellor for research, Isfahan University of Medical Sciences, HezarJarib St., Isfahan Isfahan Iran (Islamic Republic of)